These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 27538460)

  • 1. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies.
    Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B
    Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based nanoparticles in the systemic delivery of siRNA.
    Lin Q; Chen J; Zhang Z; Zheng G
    Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
    Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
    J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attacking the genome: emerging siRNA nanocarriers from concept to clinic.
    Alabi C; Vegas A; Anderson D
    Curr Opin Pharmacol; 2012 Aug; 12(4):427-33. PubMed ID: 22726555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of RNAi nanomedicines.
    Barros SA; Gollob JA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances of siRNA delivery by nanoparticles.
    Yuan X; Naguib S; Wu Z
    Expert Opin Drug Deliv; 2011 Apr; 8(4):521-36. PubMed ID: 21413903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
    Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
    Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?
    Aigner A; Kögel D
    Nanomedicine (Lond); 2018 Jan; 13(1):89-103. PubMed ID: 29199893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
    Zhao J; Feng SS
    Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology for in vivo targeted siRNA delivery.
    Dahlman JE; Kauffman KJ; Langer R; Anderson DG
    Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
    Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
    J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of the systemic delivery of small interfering RNA.
    Ifediba MA; Moore A
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2012; 4(4):428-37. PubMed ID: 22228711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference technology with emphasis on delivery vehicles-prospects and limitations.
    Prabha S; Vyas R; Gupta N; Ahmed B; Chandra R; Nimesh S
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1391-9. PubMed ID: 26140615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in nanoparticle-based siRNA delivery for cancer therapy.
    Lee JM; Yoon TJ; Cho YS
    Biomed Res Int; 2013; 2013():782041. PubMed ID: 23844368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.